Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Board appointment at Momenta

This article was originally published in Scrip

Executive Summary

Momenta Pharmaceuticals (US) has named James Sulat chairman of the board. He succeeds Peter Barrett, who is leaving the board after five years, including serving as chairman since June 2005. Mr Sulat, who has been a member of Momenta's board of directors since June, most recently served as chief financial officer and director of Memory Pharmaceuticals, which signed a definitive agreement to be acquired by Roche in November.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC007535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel